Security key
98420X202
X4 Pharmaceuticals, Inc - Common Stock (XFOR)
CUSIP: 98420X202
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 2,150,633
- Total 13F value
- $4,086,190
- Share change
- +2,066,952
- SEC-reported price per share
- $1.90
- Number of holders
- 49
- Value change
- +$4,064,925
- Number of buys
- 47
- Number of sells
- 2
- Shares outstanding
- 87,101,353
Holder snapshot
6 signals
Security identity
1 source field
Report period
Q2 2025
Institutions
49
Top holders
10
XFOR full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Previous quarter: Q1 2025
X4 Pharmaceuticals, Inc SEC filings
X4 Pharmaceuticals, Inc company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98420X202
Recent filing periods:
Ownership snapshot
Top reported holders of XFOR - X4 Pharmaceuticals, Inc - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
VANGUARD GROUP INC
Disclosed value leader
Bain Capital Life Science...
Comparable rows
15/15
Latest evidence
09 Jun 2025
13F
13D/G
3/4/5
Lead comparable stake: 4.8%
13D/G row: VANGUARD GROUP INC
Showing 1-6 of 15 holder rows.
Quick read
VANGUARD GROUP INC leads the comparable SEC ownership view at 4.8%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
VANGUARD GROUP INC
4.8%
BlackRock, Inc.
3%
ORBIMED ADVISORS LLC
1.7%
Mark Baldry
0.03%
Natasha Fay Thoren
0.01%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
13D/G
Company · The Vanguard Group
|
4.8%
from 13D/G
|
$1,903,935
8,067,516 shares
|
— | 31 Mar 2025 |
| BlackRock, Inc. |
13F
13D/G
Company
|
3%
from 13D/G
|
$2,702,123
11,430,304 shares
|
— | 31 Mar 2025 |
| ORBIMED ADVISORS LLC |
13F
13D/G
Company
|
1.7%
from 13D/G
|
$1,601,968
6,776,515 shares
|
— | 31 Mar 2025 |
| Mark Baldry |
3/4/5
Chief Commercial Officer
|
0.03%
|
$62,886
25,337 shares
|
— | 16 May 2025 |
| Natasha Fay Thoren |
3/4/5
Chief Legal Officer
|
0.01%
|
$1,797
9,462 shares
|
— | 20 May 2025 |
| Keith Woods |
3/4/5
Director
|
0.01%
|
$1,140
6,000 shares
|
— | 09 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
49
Shares
2,150,633
Rows available
49
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
2
Q2 2025 holders
49
Holder diff
47
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend